Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Oct 27, 2026; 18(10): 118131
Published online Oct 27, 2026. doi: 10.4254/wjh.118131
Published online Oct 27, 2026. doi: 10.4254/wjh.118131
Letter to the Editor: Activation of lymphangiogenesis by platelets as a novel therapeutic approach for liver cirrhosis and portal hypertension
Philippe Attieh, Department of General Surgery, University of Balamand, Beirut 1003, Lebanon
Karam Karam, Said G Farhat, Department of Hepatology and Gastroenterology, University of Balamand, Beirut 1003, Lebanon
Co-first authors: Philippe Attieh and Karam Karam.
Author contributions: Attieh P and Karam K contributed equally to this article, they are the co-first authors of this manuscript; Attieh P, Karam K, and Farhat SG conceptualized the study, drafted the original manuscript, and performed the review and editing of the subsequent versions; Farhat SG supervised the project and was responsible for its administration; and all authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Said G Farhat, MD, Department of Hepatology and Gastroenterology, University of Balamand, Ashrafiye, Beirut 1003, Lebanon. saidfarhat@hotmail.com
Received: December 24, 2025
Revised: January 23, 2026
Accepted: March 2, 2026
Published online: October 27, 2026
Processing time: 296 Days and 10.5 Hours
Revised: January 23, 2026
Accepted: March 2, 2026
Published online: October 27, 2026
Processing time: 296 Days and 10.5 Hours
Core Tip
Core Tip: Despite encouraging findings, our understanding of how platelet transfusion enhances liver function in patients with chronic liver disease and cirrhosis remains incomplete. Unraveling the precise biological mechanisms involved could open new avenues for translating these observations into clinical practice. Moreover, to bring platelet-rich plasma-based therapies closer to routine care, clinical studies are needed to assess their safety in patients with cirrhosis. Standardizing platelet-rich plasma preparation methods and closely monitoring for potential complications, such as the risk of portal vein thrombosis, will also be essential to ensure consistent and safe clinical outcomes.